DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 16,485 shares of the biopharmaceutical company’s stock, valued at approximately $964,000.
Other large investors have also recently bought and sold shares of the company. Penserra Capital Management LLC increased its position in shares of Bristol-Myers Squibb by 95.3% in the third quarter. Penserra Capital Management LLC now owns 1,959 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 956 shares during the last quarter. First New York Securities LLC NY acquired a new position in Bristol-Myers Squibb during the third quarter valued at about $108,000. Welch Investments LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at about $119,000. State of Alaska Department of Revenue acquired a new position in Bristol-Myers Squibb during the third quarter valued at about $109,000. Finally, Blume Capital Management Inc. boosted its position in Bristol-Myers Squibb by 2.4% in the third quarter. Blume Capital Management Inc. now owns 2,053 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 48 shares during the last quarter. 69.67% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) traded up 0.19% on Thursday, hitting $53.30. The stock had a trading volume of 2,142,920 shares. The stock has a market capitalization of $89.16 billion, a PE ratio of 20.11 and a beta of 1.00. The firm’s 50 day moving average is $55.44 and its 200-day moving average is $54.63. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $77.12. Bristol-Myers Squibb also saw unusually large options trading activity on Wednesday. Investors purchased 3,241 call options on the stock. This represents an increase of 437% compared to the average daily volume of 603 call options.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, January 26th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.67 by $0.04. Bristol-Myers Squibb had a return on equity of 31.39% and a net margin of 22.94%. The company earned $5.24 billion during the quarter, compared to analysts’ expectations of $5.14 billion. During the same quarter last year, the firm posted $0.38 earnings per share. The firm’s revenue was up 22.3% on a year-over-year basis. Equities research analysts expect that Bristol-Myers Squibb Co will post $2.80 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Friday, April 7th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Wednesday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 58.87%.
ILLEGAL ACTIVITY NOTICE: “DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Invests $964,000 in Bristol-Myers Squibb Co (BMY)” was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/04/20/dz-bank-ag-deutsche-zentral-genossenschafts-bank-frankfurt-am-main-buys-new-position-in-bristol-myers-squibb-co-bmy-updated.html.
Several research analysts have recently issued reports on the company. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, January 9th. Evercore ISI reaffirmed a “hold” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Sunday, January 8th. Jefferies Group LLC reaffirmed a “buy” rating and set a $69.00 target price on shares of Bristol-Myers Squibb in a research note on Thursday, January 5th. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $56.28 target price for the company. in a research note on Monday, March 13th. Finally, Piper Jaffray Companies reaffirmed a “neutral” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, March 8th. Twelve analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $62.48.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 34,000 shares of the business’s stock in a transaction on Tuesday, March 28th. The shares were sold at an average price of $56.17, for a total value of $1,909,780.00. Following the completion of the sale, the director now directly owns 986,112 shares of the company’s stock, valued at $55,389,911.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Theodore R. Samuels II purchased 12,000 shares of the stock in a transaction on Monday, February 27th. The stock was acquired at an average cost of $56.77 per share, with a total value of $681,240.00. Following the completion of the purchase, the director now directly owns 12,000 shares of the company’s stock, valued at $681,240. The disclosure for this purchase can be found here. Insiders sold 190,501 shares of company stock valued at $10,690,203 over the last three months. 0.24% of the stock is currently owned by insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter.